87 related articles for article (PubMed ID: 20439194)
1. Clinical risk factors for early complications after high-dose-rate endobronchial brachytherapy in the palliative treatment of lung cancer.
Zaric B; Perin B; Jovelic A; Lalic N; Secen N; Kopitovic I; Antonic M
Clin Lung Cancer; 2010 May; 11(3):182-6. PubMed ID: 20439194
[TBL] [Abstract][Full Text] [Related]
2. High dose rate endobronchial brachytherapy in the management of lung cancer: response and toxicity evaluation in 158 patients.
Ozkok S; Karakoyun-Celik O; Goksel T; Mogulkoc N; Yalman D; Gok G; Bolukbasi Y
Lung Cancer; 2008 Dec; 62(3):326-33. PubMed ID: 18482780
[TBL] [Abstract][Full Text] [Related]
3. Endobronchial brachytherapy for symptom palliation in non-small cell lung cancer--analysis of symptom response, endoscopic improvement and quality of life.
Mallick I; Sharma SC; Behera D
Lung Cancer; 2007 Mar; 55(3):313-8. PubMed ID: 17157949
[TBL] [Abstract][Full Text] [Related]
4. [The role of high dose rate (HDR) brachytherapy in advanced non-small cell lung cancer].
Makarewicz R
Pneumonol Alergol Pol; 2002; 70(5-6):265-77. PubMed ID: 12518625
[TBL] [Abstract][Full Text] [Related]
5. Long-term results of endobronchial brachytherapy: A curative treatment?
Hennequin C; Bleichner O; Trédaniel J; Quero L; Sergent G; Zalcman G; Maylin C
Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):425-30. PubMed ID: 17084547
[TBL] [Abstract][Full Text] [Related]
6. [Endoluminal HDR brachytherapy in the palliative treatment of patients with the recurrence of a non-small-cell bronchial carcinoma after prior radiotherapy].
Micke O; Prott FJ; Schäfer U; Wagner W; Pötter R; Willich N
Strahlenther Onkol; 1995 Oct; 171(10):554-9. PubMed ID: 8571174
[TBL] [Abstract][Full Text] [Related]
7. Endobronchial brachytherapy with high-dose-rate remote afterloading for recurrent endobronchial lesions.
Delclos ME; Komaki R; Morice RC; Allen PK; Davis M; Garden A
Radiology; 1996 Oct; 201(1):279-82. PubMed ID: 8816560
[TBL] [Abstract][Full Text] [Related]
8. Results of combined photodynamic therapy (PDT) and high dose rate brachytherapy (HDR) in treatment of obstructive endobronchial non-small cell lung cancer (NSCLC).
Weinberg BD; Allison RR; Sibata C; Parent T; Downie G
Photodiagnosis Photodyn Ther; 2010 Mar; 7(1):50-8. PubMed ID: 20230994
[TBL] [Abstract][Full Text] [Related]
9. CT-guided interstitial brachytherapy of inoperable non-small cell lung cancer.
Wang ZM; Lu J; Liu T; Chen KM; Huang G; Liu FJ
Lung Cancer; 2011 Nov; 74(2):253-7. PubMed ID: 21513997
[TBL] [Abstract][Full Text] [Related]
10. [Use of intraluminal brachytherapy for treatment of patients with non-small cell lung cancer in cases of local failure after teleradiotherapy].
Makarewicz R; Kuźmińska A
Pneumonol Alergol Pol; 1996; 64(7-8):444-9. PubMed ID: 8983445
[TBL] [Abstract][Full Text] [Related]
11. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
12. Palliative high-dose-rate endobronchial brachytherapy for recurrent carcinoma: the University of Louisville experience.
Guarnaschelli JN; Jose BO
J Palliat Med; 2010 Aug; 13(8):981-9. PubMed ID: 20666622
[TBL] [Abstract][Full Text] [Related]
13. [Patient-related independent clinical risk factors for early complications following interventional pulmonology procedures].
Huang JJ; Zhang H; Zhang W; Wang X; Gong YH; Wang GF
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Dec; 48(6):1006-1011. PubMed ID: 27987505
[TBL] [Abstract][Full Text] [Related]
14. Optimization of dose and fractionation of endobronchial brachytherapy with or without external radiation in the palliative management of non-small cell lung cancer: a prospective randomized study.
Mallick I; Sharma SC; Behera D; Ghoshal S; Oinam AS
J Cancer Res Ther; 2006; 2(3):119-25. PubMed ID: 17998689
[TBL] [Abstract][Full Text] [Related]
15. The use of high dose rate endobronchial brachytherapy to palliate symptomatic recurrence of previously irriadiated lung cancer.
Kubaszewska M; Skowronek J; Chicheł A; Kanikowski M
Neoplasma; 2008; 55(3):239-45. PubMed ID: 18348661
[TBL] [Abstract][Full Text] [Related]
16. High dose rate intraluminal brachytherapy in the treatment of malignant airway obstructions.
Petera J; Spásová I; Neumanová R; Skricková J; Salajka F; Hrazdírová A; Kaplanová J; Coupková H; Coupek P; Kucera M
Neoplasma; 2001; 48(2):148-53. PubMed ID: 11478697
[TBL] [Abstract][Full Text] [Related]
17. Accelerated partial breast irradiation: an analysis of variables associated with late toxicity and long-term cosmetic outcome after high-dose-rate interstitial brachytherapy.
Wazer DE; Kaufman S; Cuttino L; DiPetrillo T; Arthur DW
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):489-95. PubMed ID: 16246495
[TBL] [Abstract][Full Text] [Related]
18. Predicting the need for palliative thoracic radiation after first-line chemotherapy for advanced nonsmall cell lung carcinoma.
Higginson DS; Chen RC; Morris DE; Halle J; Rosenman JG; Socinski MA; Marks LB
Cancer; 2012 May; 118(10):2744-51. PubMed ID: 21935913
[TBL] [Abstract][Full Text] [Related]
19. Irradiated volume and the risk of fatal hemoptysis in patients submitted to high dose-rate endobronchial brachytherapy.
Carvalho Hde A; Gonçalves SL; Pedreira W; Gregório MG; de Castro I; Aisen S
Lung Cancer; 2007 Mar; 55(3):319-27. PubMed ID: 17129634
[TBL] [Abstract][Full Text] [Related]
20. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
